洛萨坦通过调节TGF-β/Smad信号传递来减轻性大鼠的类似抑郁的行为
Penghui Cao1, Shichuan Shen1, Ziyan Fang2
1Department of Psychiatry, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
IBRO neuroscience reports
|December 29, 2025
概括
通过TGF-β/Smad信号传递与抑郁症有关. 洛萨坦治疗通过调节这种途径,改善了性大鼠的抑郁行为,这表明它有可能治疗的并发性抑郁症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 伴随性抑郁症是管理中的一个重大挑战.
- TGF-β/Smad信号通路已涉及到各种神经系统疾病,包括抑郁症.
研究的目的:
- 调查TGF-β/Smad信号通路在与并发的抑郁症中的作用.
- 在模型中评估洛萨坦对抑郁症状的治疗效果.
主要方法:
- 在使用Li-Popilocarpine的老鼠中诱导了状态 (SE).
- 在20天的干预期间,老鼠被分为SE盐溶液和SE洛萨坦组.
- 评估了抑郁水平,TGF-β mRNA,TGF-β/Smad信号蛋白和星球细胞密度.
主要成果:
- 与对照组相比,SE老鼠表现出更多类似抑郁症的行为.
- 在SE大鼠中观察到TGF-βmRNA,p-Smad2,p-Smad3和GFAP+天体细胞表达的升高.
- 洛萨坦治疗显著改善了类似抑郁症的行为,并减少了SE大鼠中的这些分子标志物.
结论:
- TGF-β/Smad信号通路在相关抑郁症中起着至关重要的作用.
- 洛萨坦通过调节这种途径,有效地改善了性大鼠的抑郁类行为.
- 洛萨坦作为重定向的中枢神经系统药物,有望用于治疗的并发性抑郁症,值得临床试验.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators
590
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
590
Antidepressant Drugs: MAOIs and Other Agents
765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K


